Rare Disease Bets and FDA Pressure

Kilder

• BioPharma Dive: An eye drug biotech banks $118M and stocks its executive suite
• STAT: STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
• Raps: Recon: FDA says Replimune's pivotal melanoma study failed to show benefit; FDA guidance on peptides could affect development of GLP-1 generics - RAPS
• STAT: FDA staff reiterate concerns about Replimune skin cancer treatment - STAT
• STAT: STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
• Raps: Recon: FDA says Replimune's pivotal melanoma study failed to show benefit; FDA guidance on peptides could affect development of GLP-1 generics - RAPS
• STAT: FDA staff reiterate concerns about Replimune skin cancer treatment - STAT

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.